VEGF Receptor 3 Antibody (Rabbit mAb) [M6F2]

Catalog No.: F9678

    Application: Reactivity:

    当該製品は品切れ状态で、メールアドレスをご教示いただければ、お客様に返信いたします。

    代表番号: 045-509-1970|電子メール:sales@selleck.co.jp

    キーポイント

    WB
    SDS-PAGE の分離ゲルの推奨濃度:5%

    使用情報

    Dilution
    1:1000
    Application
    WB
    Source
    Rabbit Monoclonal Antibody
    Reactivity
    Human
    Storage Buffer
    PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3
    Storage (from the date of receipt)
    -20°C (avoid freeze-thaw cycles), 2 years
    Predicted MW
    153 kDa

    プロトコール

    WB
    Experimental Protocol:
     
    Sample preparation
    1. Tissue: Lyse the tissue sample by adding an appropriate volume of ice-cold RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail),and homogenize the tissue at a low temperature or lyse it by sonication on ice, then incubate on ice for 30 minutes.
    2. Adherent cell: Aspirate the culture medium and wash the cells with ice-cold PBS twice. Lyse the cells by adding an appropriate volume of RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail) , sonicate to lyse the cells, and incubate on ice for 30 minutes.
    3. Suspension cell: Transfer the culture medium to a pre-cooled centrifuge tube. Centrifuge and aspirate the supernatant. Wash the cells with ice-cold PBS twice. Lyse the cells by adding an appropriate volume of RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail) , sonicate to lyse the cells, and incubate on ice for 30 minutes.
    4. Place the lysate into a pre-cooled microcentrifuge tube. Centrifuge at 4°C for 15 min. Collect the supernatant;
    5. Remove a small volume of lysate to determine the protein concentration;
    6. Combine the lysate with protein loading buffer. Boil 20 µL sample under 95-100°C for 5 min. Centrifuge for 5 min after cool down on ice.
     
    Electrophoretic separation
    1. According to the concentration of extracted protein, load appropriate amount of protein sample and marker onto SDS-PAGE gels for electrophoresis. Recommended separating gel (lower gel) concentration: 5%. Reference Table for Selecting SDS-PAGE Separation Gel Concentrations
    2. Power up 80V for 30 minutes. Then the power supply is adjusted (110 V~150 V), the Marker is observed, and the electrophoresis can be stopped when the indicator band of the predyed protein Marker where the protein is located is properly separated. (Note that the current should not be too large when electrophoresis, too large current (more than 150 mA) will cause the temperature to rise, affecting the result of running glue. If high currents cannot be avoided, an ice bath can be used to cool the bath.)
     
    Transfer membrane
    1. Take out the converter, soak the clip and consumables in the pre-cooled converter;
    2. Activate PVDF membrane with methanol for 1 min and rinse with transfer buffer;
    3. Install it in the order of "black edge of clip - sponge - filter paper - filter paper - glue -PVDF membrane - filter paper - filter paper - sponge - white edge of clip";
    4. The protein was electrotransferred to PVDF membrane. ( 0.45 µm PVDF membrane is recommended ) Reference Table for Selecting PVDF Membrane Pore Size Specifications
    Recommended conditions for wet transfer: 200 mA, 120 min.
    ( Note that the transfer conditions can be adjusted according to the protein size. For high-molecular-weight proteins, a higher current and longer transfer time are recommended. However, ensure that the transfer tank remains at a low temperature to prevent gel melting.)
     
    Block
    1. After electrotransfer, wash the film with TBST at room temperature for 5 minutes;
    2. Incubate the film in the blocking solution for 1 hour at room temperature;
    3. Wash the film with TBST for 3 times, 5 minutes each time.
     
    Antibody incubation
    1. Use 5% skim milk powder to prepare the primary antibody working liquid (recommended dilution ratio for primary antibody 1:1000), gently shake and incubate with the film at 4°C overnight;
    2. Wash the film with TBST 3 times, 5 minutes each time;
    3. Add the secondary antibody to the blocking solution and incubate with the film gently at room temperature for 1 hour;
    4. After incubation, wash the film with TBST 3 times for 5 minutes each time.
     
    Antibody staining
    1. Add the prepared ECL luminescent substrate (or select other color developing substrate according to the second antibody) and mix evenly;
    2. Incubate with the film for 1 minute, remove excess substrate (keep the film moist), wrap with plastic film, and expose in the imaging system.

    Datasheet & SDS

    生物学的記述

    Specificity
    VEGF Receptor 3 Antibody (Rabbit mAb) [M6F2] detects endogenous levels of total VEGF Receptor 3 protein.
    タンパク質の局在
    細胞膜、細胞質、細胞内膜系
    Uniprot ID
    P35916
    Clone
    M6F2
    Synonym(s)
    CHTD7, Feline McDonough Sarcoma (FMS)-like tyrosine kinase 4, FLT-4, FLT4, FLT41, tyrosine kinase 4, LMPH1A, LMPHM1, PCL, primary congenital lymphedema, soluble VEGFR3 variant 1, soluble VEGFR3 variant 2, soluble VEGFR3 variant 3, VEGF receptor-3, VEGFR-3, VEGFR3, VGFR3
    Background
    VEGF receptor 3 (VEGFR3, FLT4) is a type III receptor tyrosine kinase of the VEGF receptor family that is expressed predominantly on lymphatic endothelial cells in postnatal tissues and functions as a principal regulator of lymphangiogenesis and lymphatic vessel homeostasis through selective binding of the processed forms of VEGF‑C and VEGF‑D. The receptor contains seven extracellular immunoglobulin-like domains that engage dimeric VEGF‑C or VEGF‑D ligands, a single transmembrane segment, and an intracellular split tyrosine kinase domain with multiple regulatory tyrosines whose phosphorylation controls recruitment of signaling complexes, so ligand-induced dimerization triggers trans-autophosphorylation and converts VEGFR3 into an active signaling hub at the lymphatic endothelial surface. VEGF‑C/VEGFR3 signaling activates phosphatidylinositol 3‑kinase via direct receptor interaction and stimulates the PI3K–Akt axis, leading to phosphorylation of downstream targets including p70S6K, endothelial nitric oxide synthase, PLCγ1, and ERK1/2, and this coordinated kinase output promotes lymphatic endothelial cell survival, proliferation, migration, and tube formation, which underlies lymphatic sprouting, branching, and vessel enlargement. The same receptor–ligand system also engages the MEK–ERK pathway and modulates cytoskeletal dynamics and junctional organization, thereby shaping lymphatic vessel patterning, valve formation, and fluid transport capacity during development and in adult tissue remodeling. VEGFR3 expression, initially present on embryonic blood vascular endothelium, becomes progressively restricted to lymphatic endothelium after midgestation, and in adult tissues, VEGFR3 marks lymphatic capillaries and collecting vessels in skin, intestine, and other organs where it maintains lymphatic integrity and responds to inflammatory and tissue repair cues. In pathological contexts, upregulation of VEGFR3 and its ligands in and around tumors drives lymphangiogenesis and lymphatic vessel dilation, facilitating entry and dissemination of tumor cells to regional lymph nodes, while blockade of VEGFR3 signaling with neutralizing antibodies or soluble receptor constructs reduces tumor-associated lymphatic density and lymph node metastasis, and can also lower blood vessel density in some tumor models where VEGFR3 contributes to angiogenesis. VEGFR3 is also expressed in specialized non-lymphatic compartments, including the subventricular zone and hippocampal neural stem cells and cardiac endothelium, where VEGF‑C/VEGFR3 activation engages Akt and ERK signaling to regulate neural stem cell activation, adult neurogenesis, and aspects of cardiac lymphatic remodeling and function, linking this receptor to broader roles in tissue regeneration and organ homeostasis beyond classical lymphatic biology.
    References

    技術サポート

    ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

    Handling Instructions

    他に質問がある場合は、お気軽にお問い合わせください。

    * 必須

    大学・企業名を記入してください
    名前を記入してください
    電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
    お問い合わせ内容をご入力ください